Neovacs

Contact
neovacs.com
+33153109300

Neovacs SA

3-5 Impasse Reille
75014 Paris
France
+33153109300
neovacs.com
Contact
Profile News
Contact

About Neovacs

The biotechnology company Neovacs is focused on an active immunotherapy technology platform with applications in autoimmune disease and other chronic conditions. It was founded as a spin‐off from Pierre & Marie Curie University in Paris by Professor Daniel Zagury, MD, one of the world’s leading immunologists.

Read more about Neovacs
Facts about Neovacs
  • Focus : Manufacturer
  • Industry : Biotechnology

News about Neovacs

Neovacs

16-Nov-2016 | business & finance

Neovacs acquires Interferon Alpha manufacturing technology from AMEGABIOTECH

Neovacs, a manufacturer of active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company AMEGABIOTECH ...

Read news
Neovacs

29-Jun-2015 | business & finance

Neovacs raises 7.5 million Euro

Neovacs announced that it has received commitments from three U.S. institutional investors for a capital increase totaling 7,500,000 euros.Participation in ...

Read news
Neovacs

24-Mar-2015 | business & finance

Neovacs froms U.S. subsidiary

Neovacs announced the establishment of its wholly-owned U.S. subsidiary, Neovacs, Inc. Neovacs, Inc. is headquartered in Boston and has been incorporated ...

Read news
Neovacs

12-Mar-2015 | people

Neovacs strengthens scientific leadership through executive appointments

Neovacs announced the enhancement of its scientific leadership team with the appointment of Therese Croughs, M.D., as Chief Medical Officer, effective ...

Read news
Neovacs

19-Dec-2014 | research and development

NEOVACS announces top-line phase IIb clinical trial results of TNF-Kinoid in Rheumatoid Arthritis

NEOVACS announced top line data on the Phase IIb clinical trial of TNF-Kinoid in Rheumatoid Arthritis (RA). This trial confirmed the immunogenicity and ...

Read news
Neovacs

21-Oct-2013 | people

Miguel Sieler named C.E.O of Neovacs

NEOVACS annonced that Miguel Sieler, former Chairman and Chief Executive Officer of Bayer France has been named Chief Executive Officer of Neovacs, ...

Read news
Neovacs

22-Feb-2011 | research and development

Phase I/II clinical study of Neovac's IFNα-Kinoid for lupus fully enrolled

Initial results expected in April 2011

Read news
Neovacs

12-Jan-2011 | research and development

Neovacs initiates a Phase II clinical study of its TNF‐Kinoid in Crohn’s Disease Patients

Neovacs announced the start of a Phase 2 international clinical trial to study the efficacy of the TNF‐Kinoid in patients suffering from Crohn’s Disease. Co ...

Read news
Show more news about Neovacs

Here you will find Neovacs SA